The Latest Cardiac and Vascular News
Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system ALAMEDA, Calif., Nov. 5, 2024…
ALAMEDA, Calif., Oct. 14, 2024 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company’s…
Campaign is led by prominent medical societies to minimize discrepancies in treating blood clot conditions, such as in pulmonary embolism, where there are often delays in care (up to 26% of patients in one study) and misdiagnosis (up to 53% of patients in one study)1,2 ALAMEDA, Calif.,…
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to […]
Lightning Flash™ 2.0 features advanced computer assisted vacuum thrombectomy (CAVT) software, designed for increased efficiency and sensitivity to enhance removal of venous thrombus and treatment of pulmonary emboli (PE) Combined with streamlined audio-visual feedback, Lightning Flash 2.0…
ALAMEDA, Calif., Aug. 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the second quarter ended June 30, 2023. Revenue of $261.5 million in the second quarter of 2023, an increase of 25.5% as […]
Lightning Bolt™ 7 is the most advanced arterial thrombectomy system on the market Latest technology combines modulated aspiration with superior catheter design to maximize blood clot removal in a single session ALAMEDA, Calif., June 1, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global […]
ALAMEDA, Calif., May 2, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the first quarter ended March 31, 2023. Revenue of $241.4 million in the first quarter of 2023, an increase of 18.4%, or […]
Acute Limb Ischemia (ALI) occurs when there is a sudden lack of blood flow to a limb, which is often caused by a blood clot. Although treatable, ALI is associated with high amputation rates and mortality if not treated immediately. […]
ALAMEDA, Calif., Feb. 23, 2023 /PRNewswire/ — Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative therapies, today reported financial results for the fourth quarter and full year ended December 31, 2022. Financial Highlights: Revenue of $221.2 million for the fourth quarter of 2022, an increase […]
